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The CORAL Trial in PerspectiveDr. WhiteThe subject of renal artery stenting has received considerable attention with the release
of the results of the CORAL Trial. I have asked Dr. Chris White, associate editor
of this journal, to put these ﬁndings in perspective.
dSpencer B. King III, MD, MACC






MDNo, “the sky is not falling” after the release of the results of CORAL (Cardiovascular Outcomes
in Renal Atherosclerotic Lesions) (1). There is absolutely no justiﬁcation for the “Chicken Little”
hysteria portending the demise of renal artery stenting (2). The CORAL study did not support a
preference for renal stenting as the initial treatment for presumed atherosclerotic renovascular
hypertension, but neither do the current American College of Cardiology and American Heart
Association guidelines (3). These guidelines recommend renal artery stenting as a reasonable
option for patients with one of the following: an atherosclerotic severe renal artery stenosis
(>70% angiographic diameter renal artery stenosis or 50% to 70% stenosis with hemodynamic
conﬁrmation of lesion severity) associated with 1) resistant or uncontrolled hypertension and the
failure of 3 antihypertensive drugs, 1 of which is a diuretic agent, and 2) hypertension and
intolerance to medication.
The CORAL study found that the primary composite end point (death from cardiovascular
or renal causes, myocardial infarction, stroke, hospitalization for congestive heart failure,
progressive renal insufﬁciency, or the need for renal replacement therapy) in patients with renal
artery stenosis (>60% diameter stenosis) and poorly controlled hypertension, on 2 or more
medications, did not differ between groups treated with multifactorial medical therapy alone
compared with multifactorial medical therapy with renal stenting. In the CORAL study,
multifactorial medical therapy consisted of an angiotensin receptor–blocking agent, a thiazide-
type diuretic drug, amlodipine, atorvastatin, antiplatelet therapy, and diabetes managed
according to clinical practice guidelines. The number of blood pressure medications in the
group assigned to medical therapy alone increased from baseline at 2.1  1.6 to 3.5  1.4
(not different from the stent group, at 3.3  1.5) at the completion of the trial. Interestingly,
both groups had similar decreases in systolic blood pressure, 15.6  25.8 mm Hg in the
medical therapy group and 16.6  21.2 mm Hg in the stent group, implying that the medical
treatment group had not actually failed 3-drug antihypertensive medical therapy. The in-
vestigators reasonably concluded multifactorial medical therapy to be the initial treatment of
choice for patients with uncontrolled hypertension taking 2 or more medications rather than
renal stenting.
The CORAL trial was well planned and reasonably well run. As with many large, federally
funded trials, the original plan had to be altered along the way because of slower than expected
patient enrollment. A major issue impeding enrollment was a lack of equipoise between medical
therapy and stent placement. Patients with severe renal artery lesions, who clinicians “knew”
needed revascularization, were not likely to be enrolled in CORAL, as indicated by modest
average renal artery stenosis of 67% found by the core laboratory. Patients with mild renal artery
stenoses also were not likely to be enrolled in the trial, because clinicians “knew” they did not
need revascularization. This leaves the middle grounddthe uncertain lesions for which there is
equipoisedfor randomization in CORAL, and that is what they got. Because there was no
opportunity to enroll into a registry those patients in whom clinicians “knew” the correct therapy,is a consultant for St. Jude and Neovasc; and performs research with Baxter.
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to understand the impact of the 2 treatment strategies
in patients who represent the majority of patients who
are treated for renovascular hypertension.
The “Achilles’ heel” of renal artery intervention is
our dependence on invasive angiography to deter-
mine which renal artery stenoses cause renal
ischemia. Angiography has been shown to poorly
discriminate the hemodynamic severity of moderate
renal artery stenoses (4). There is no relationship
between moderate (50% to 70%) renal artery ste-
nosis determined with quantitative angiography and
the hemodynamic severity of a renal artery stenosis.
The major limitation of the CORAL study (as was
true of the Angioplasty and Stenting for Renal
Artery Lesions and Stenting in Renal Dysfunction
Caused by Atherosclerotic Renal Artery Stenosis
trials) was the inability to select hemodynamically
severe renal artery stenoses for treatment. This is
particularly relevant for moderate lesions (mean
67% stenosis determined by the core laboratory)
enrolled in the CORAL study. Without measuring
the hemodynamic severity of the renal artery
stenosis, one cannot hope to separate patients with
true renovascular hypertension from those with
atherosclerotic renal artery disease and essential
hypertension (5–7).
Experienced interventionalists have repeatedly
demonstrated in device trials sponsored by the US
Food andDrug Administration the technical ability to
successfully place renal artery stents95% of the time
(94.6% in the CORAL trial), which is out
of proportion to the clinical beneﬁt reported for hy-
pertension control (about 70%) and improvement of
renal function (about 75%), suggesting that either 1)
we are stenting renal stenoses that are not causing renal
ischemia, or 2) the clinical syndromes
(hypertension and chronic kidney disease) we are
treating are not related to the renal artery obstructive
lesions. Both of these issues likely inﬂuenced the
CORAL outcomes. The systolic blood pressure
reduction and medical therapy to achieve that effect
were very similar in both treatment groups. This im-
plies that renal stenting had little to no effect in
addition to the antihypertensive therapy. One won-
ders, with the inaccuracy of 2-dimensional angiog-
raphy for renal artery stenosis assessment, how
many of the renal stenoses included in this trial
were not causing kidney hypoperfusion and what
percent of the study patients’ hypertension was
“essential” and not related to renal ischemia. We
will never know for sure, but it is likely that the
CORAL study actually demonstrated that multi-
factorial medical therapy alone was equivalent tomedical therapy plus stenting in patients with
essential hypertension and nonobstructive athero-
sclerotic renal artery stenoses.
How should the results of the CORAL trial affect
our clinical practice for patients suspected of having
renovascular hypertension? Patients with presumed
atherosclerotic renovascular hypertension should be
given a trial of multifactorial medical therapy to lower
their blood pressure, as suggested by the results of
CORAL. However, for patients whose blood pressure
is not controlled with medical therapy, I would follow
the recommendation of the American College of
Cardiology and American Heart Association guide-
lines document, which states that it is reasonable to
offer renal artery stenting to patients with athero-
sclerotic severe renal artery stenoses (>70% angio-
graphic diameter renal artery stenosis or 50% to 70%
stenosis with hemodynamic conﬁrmation of lesion
severity) associated with resistant hypertension and
failure of 3 drugs, 1 of which is a diuretic agent, or
patients with hypertension and intolerance to medi-
cation (3).
Two major questions remain since the completion
of the CORAL study: 1) Does renal revasculariza-
tion with stenting plus medical therapy offer an
effective treatment for renal artery stenosis in
patients whose blood pressure remains uncontrolled
despite multifactorial medical therapy? 2) What is
the beneﬁt of renal artery stenting plus medical
therapy versus multifactorial medical therapy for
renal artery stenoses that have been hemodynami-
cally conﬁrmed as a cause of renovascular ischemia?
It is not likely that federal funding will be available
any time soon for another major clinical trial in this
patient population to satisfy the questions raised by
CORAL. What is promising, however, is the
concept of a randomized registry trial, as outlined by
Lauer and D’Agostino (8), and the opportunity
created by the expansion of the National Cardio-
vascular Database Registry’s Carotid Artery Revas-
cularization and Endarterectomy registry into the
new Peripheral Vascular Interventions registry, a
sister registry to the CathPCI Registry, which will
eventually enroll a national sample of renal stent
patients. This registry population of renal stent
patients may lend itself to relatively low-cost, efﬁ-
cient, prospective queries that will help us move this
very important ﬁeld forward.Address correspondence to:
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